Suchergebnisse - "Sablerolles, Roos S G"

PubPharm (17)

11

Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming

enthalten in: The New England journal of medicine | 2022

von Sablerolles, R. | Rietdijk, W. | Goorhuis, A. | +38

12

Analyzing the immunogenicity of bivalent booster vaccinations in healthcare workers : The SWITCH ON trial protocol

enthalten in: Frontiers in immunology | 2022

von Tan, N. | Sablerolles, R. | Rietdijk, W. | +15

13

No association between use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers prior to hospital admission and clinical course of COVID-19 in the COvid MEdicaTion (COMET) study

enthalten in: British journal of clinical pharmacology | 2021

von Sablerolles, R. | Hogenhuis, F. | Lafeber, M. | +6

14

Association between Clinical Frailty Scale score and hospital mortality in adult patients with COVID-19 (COMET) : an international, multicentre, retrospective, observational cohort study

enthalten in: The lancet. Healthy longevity | 2021

von Sablerolles, R. | Lafeber, M. | van Kempen, J. | +109

CommentIn: Lancet Healthy Longev. 2021 Mar;2(3):e119-e120. - PMID 33817683

15

Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens : The SWITCH Trial Protocol

enthalten in: Frontiers in immunology | 2021

von Sablerolles, R. | Goorhuis, A. | GeurtsvanKessel, C. | +11

16

No association between use of angiotensin‐converting enzyme inhibitors or angiotensin II receptor blockers prior to hospital admission and clinical course of COVID‐19 in the COvid MEdicaTion (COMET) study

enthalten in: British Journal of Clinical Pharmacology | 2021

von Sablerolles, R. | Hogenhuis, F. | Lafeber, M. | +5

17

COvid MEdicaTion (COMET) study : protocol for a cohort study

enthalten in: European journal of hospital pharmacy : science and practice | 2020

von Sablerolles, R. | Hogenhuis, F. | Lafeber, M. | +106